This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Schmitt-Hoffmann, A.
Right arrow Articles by Beglinger, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schmitt-Hoffmann, A.
Right arrow Articles by Beglinger, C.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, January 2006, p. 279-285, Vol. 50, No. 1
0066-4804/06/$08.00+0     doi:10.1128/AAC.50.1.279-285.2006
Copyright © 2006, American Society for Microbiology. All Rights Reserved.

Single-Ascending-Dose Pharmacokinetics and Safety of the Novel Broad-Spectrum Antifungal Triazole BAL4815 after Intravenous Infusions (50, 100, and 200 Milligrams) and Oral Administrations (100, 200, and 400 Milligrams) of Its Prodrug, BAL8557, in Healthy Volunteers

Anne Schmitt-Hoffmann,1* Brigitte Roos,1 Markus Heep,1 Michael Schleimer,1 Erhard Weidekamm,1 Tom Brown,1 Michael Roehrle,2 and Christoph Beglinger3

Basilea Pharmaceutica, Ltd., 4002 Basel, Switzerland,1 AAI, 89231 Neu-Ulm, Germany,2 Department of Gastroenterology, University Hospital, 4031 Basel, Switzerland3

Received 21 April 2005/ Returned for modification 25 May 2005/ Accepted 17 July 2005

BAL8557 is the water-soluble prodrug of a novel antifungal triazole, BAL4815. BAL4815 is active against a broad spectrum of major opportunistic and pathogenic fungi, including strains that are resistant to other azoles. Cohorts of healthy male subjects received single-ascending oral (p.o.) doses of BAL8557 that were equivalent to 100, 200, or 400 mg of BAL4815 or single-ascending, 1-h constant-rate intravenous (i.v.) infusions of BAL8557 which were equivalent to 50, 100, or 200 mg of BAL4815. In each cohort, six subjects were randomly assigned to receive active drug and two subjects were assigned to receive the placebo. All doses were well tolerated, and no severe or serious adverse events occurred. Maximum plasma concentrations of BAL4815 were observed 1.5 to 3 h after p.o. drug intake or at the end of the 1-h infusion. After both routes of administration, values for maximum drug concentration observed in plasma and area under the concentration-time curve increased slightly more than proportionally to the administered dose. Mean elimination half-lives were particularly long (56 to 77 h after p.o. administration and 76 to 104 h after i.v. administration). The volume of distribution was large (155 to 292 liters after p.o. administration and 304 to 494 liters after i.v. administration) and systemic clearance was low (1.9 to 2.8 liter/h after p.o. administration and 2.8 to 5.0 liter/h after i.v. administration). Urinary recovery of BAL4815 was less than 0.4% of the infused dose. Based on the exposure data, oral bioavailability of BAL4815 is assumed to be very high. The pharmacokinetics of BAL4815 are well suited to maintaining concentrations of BAL4815 for a long period of time in the body and to enabling an effective treatment of systemic mycoses.

* Corresponding author. Mailing address: Basilea Pharmaceutica, Ltd., P.O. Box 3255, 4002 Basel, Switzerland. Phone: 41 61 606 1379. Fax: 41 61 606 1378. E-mail: schmita{at}basileapharma.com.

Antimicrobial Agents and Chemotherapy, January 2006, p. 279-285, Vol. 50, No. 1
0066-4804/06/$08.00+0     doi:10.1128/AAC.50.1.279-285.2006
Copyright © 2006, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Schmitt-Hoffmann, A., Roos, B., Spickermann, J., Heep, M., Peterfai, E., Edwards, D. J., Stoeckel, K. (2009). Effect of Mild and Moderate Liver Disease on the Pharmacokinetics of Isavuconazole after Intravenous and Oral Administration of a Single Dose of the Prodrug BAL8557. Antimicrob. Agents Chemother. 53: 4885-4890 [Abstract] [Full Text]  
  • Warn, P. A., Sharp, A., Parmar, A., Majithiya, J., Denning, D. W., Hope, W. W. (2009). Pharmacokinetics and Pharmacodynamics of a Novel Triazole, Isavuconazole: Mathematical Modeling, Importance of Tissue Concentrations, and Impact of Immune Status on Antifungal Effect. Antimicrob. Agents Chemother. 53: 3453-3461 [Abstract] [Full Text]  
  • Majithiya, J., Sharp, A., Parmar, A., Denning, D. W., Warn, P. A. (2009). Efficacy of isavuconazole, voriconazole and fluconazole in temporarily neutropenic murine models of disseminated Candida tropicalis and Candida krusei. J Antimicrob Chemother 63: 161-166 [Abstract] [Full Text]  
  • Thompson, G. R. III, Fothergill, A. W., Wiederhold, N. P., Vallor, A. C., Wickes, B. L., Patterson, T. F. (2008). Evaluation of Etest Method for Determining Isavuconazole MICs against Cryptococcus gattii and Cryptococcus neoformans. Antimicrob. Agents Chemother. 52: 2959-2961 [Abstract] [Full Text]  
  • Guinea, J., Pelaez, T., Recio, S., Torres-Narbona, M., Bouza, E. (2008). In Vitro Antifungal Activities of Isavuconazole (BAL4815), Voriconazole, and Fluconazole against 1,007 Isolates of Zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium Species. Antimicrob. Agents Chemother. 52: 1396-1400 [Abstract] [Full Text]  
  • Illnait-Zaragozi, M.-T., Martinez, G. F., Curfs-Breuker, I., Fernandez, C. M., Boekhout, T., Meis, J. F. (2008). In Vitro Activity of the New Azole Isavuconazole (BAL4815) Compared with Six Other Antifungal Agents against 162 Cryptococcus neoformans Isolates from Cuba. Antimicrob. Agents Chemother. 52: 1580-1582 [Abstract] [Full Text]  
  • Pasqualotto, A. C., Denning, D. W. (2008). New and emerging treatments for fungal infections. J Antimicrob Chemother 61: i19-i30 [Abstract] [Full Text]  
  • Seifert, H., Aurbach, U., Stefanik, D., Cornely, O. (2007). In Vitro Activities of Isavuconazole and Other Antifungal Agents against Candida Bloodstream Isolates. Antimicrob. Agents Chemother. 51: 1818-1821 [Abstract] [Full Text]  
  • Warn, P. A., Sharp, A., Mosquera, J., Spickermann, J., Schmitt-Hoffmann, A., Heep, M., Denning, D. W. (2006). Comparative in vivo activity of BAL4815, the active component of the prodrug BAL8557, in a neutropenic murine model of disseminated Aspergillus flavus. J Antimicrob Chemother 58: 1198-1207 [Abstract] [Full Text]  
  • Schmitt-Hoffmann, A., Roos, B., Maares, J., Heep, M., Spickerman, J., Weidekamm, E., Brown, T., Roehrle, M. (2006). Multiple-Dose Pharmacokinetics and Safety of the New Antifungal Triazole BAL4815 after Intravenous Infusion and Oral Administration of Its Prodrug, BAL8557, in Healthy Volunteers. Antimicrob. Agents Chemother. 50: 286-293 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»